In silico platform for biopharma scientists to design mRNA therapeutic candidates
mRNA-based therapeutics : Heralding a new class of drugs
Success of mRNA vaccines against SARS-CoV-2 has demonstrated the great potential of mRNA based therapies. The potential of mRNA sequence to produce specific proteins using cells’ own translation machinery without causing any permanent alteration to the DNA sequence makes it an important modality.
Key challenges in mRNA design include:
- Selecting the optimal coding sequence of mRNA from a formidably large search space
- Multidimensionality of the problem space leading to increased expenses, manpower, and computation time
- Ensuring ex vivo and in vivo stability as well as translation efficiency
- Lack of customizable and scalable pipelines for complete mRNA characterisation and design
The platform consists of an integrated end-to-end pipeline for complete mRNA design. It offers researchers the ability to tailor an entire mRNA through:
- Target Protein Selection
- mRNA Coding Sequence Optimization
- Compatible non-coding Parts Design
The solution is deployed on a computational platform for high throughput screening and cloud-based Kubernetes environment with schedulers such as SLURM for auto-scaling and workload management.
An in silico platform for designing effective mRNA therapeutic candidates leveraging advanced computational algorithms and scalable infrastructure
Key steps of the mRNA pipeline include:
Check the presence of Kozak consensus sequence in the designed mRNA